Outcome of the Board Meeting held on Thursday, February 12, 2026, i.e, today, to consider and approve the un-audited financial results for the quarter and nine months ended December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 4.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved unaudited financial results for Q3 FY26 and nine months ended December 31, 2025. On a standalone basis, quarterly revenue from operations fell sharply to Rs. 83.28 lakhs from Rs. 120.79 lakhs in the same quarter last year (-31%), while the standalone net loss widened to Rs. (310.98) lakhs versus Rs. (159.29) lakhs a year ago. For the nine-month period, standalone losses ballooned to Rs. (912.51) lakhs versus Rs. (422.28) lakhs, driven by a surge in cost of materials consumed (Rs. 1,019.39 lakhs vs Rs. 0.01 lakhs) and finance costs jumping from Rs. 9.54 lakhs to Rs. 270.18 lakhs. On a consolidated basis, nine-month revenue grew ~41% to Rs. 2,069.85 lakhs, but the consolidated loss also widened to Rs. (1,048.70) lakhs with exceptional items of Rs. 255.40 lakhs. The company disclosed discontinuing its lease with Koye Lifesciences Private Limited effective December 1, 2025.
Sharply widening losses, a steep spike in finance costs, and weak standalone revenue suggest serious financial stress and rising debt burden, which is negative for shareholders. The consolidated top-line growth offers some comfort, but persistent and deepening losses keep the near-term outlook weak for the stock.